Authors' Reply to Letter to the Editor: Sequential Ramucirumab Plus Docetaxel After <scp>PD</scp> ‐1 Inhibitors

Authors

Institutions

Publication Details

Journal
Cancer Science
Published
2026-04-20
DOI
https://doi.org/10.1111/cas.70398
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Authors' Reply to Letter to the Editor: Sequential Ramucirumab Plus Docetaxel After PD ‐1 Inhibitors

Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama
Cancer Science
Cancer Immunotherapy and Biomarkers
article

Authors' Reply to Letter to the Editor: Sequential Ramucirumab Plus Docetaxel After PD ‐1 Inhibitors

Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama
article en

Abstract

No abstract available for this paper.
Cancer Science
Osaka City University (JP), The University of Osaka (JP)
Eli Lilly Japan
Good health and well-being
Openalex Percentile: Top 18%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Authors' Reply to Letter to the Editor: Sequential Ramucirumab Plus Docetaxel After <scp>PD</scp> ‐1 Inhibitors — Kinnosuke Matsumoto, Yujiro Naito, et al. · Cancer Science (2026) | TGRS Research Map | TGRS